No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
STRO Sutro Biopharma
- 3.470
- -0.250-6.72%
Close Apr 24 16:00 ET
- 3.630
- +0.160+4.61%
Post 18:16 ET
266.91MMarket Cap-1949P/E (TTM)
3.750High3.400Low731.25KVolume3.720Open3.720Pre Close2.57MTurnover1.22%Turnover RatioLossP/E (Static)76.92MShares6.13052wk High1.78P/B207.77MFloat Cap2.00552wk Low--Dividend TTM59.87MShs Float28.300Historical High--Div YieldTTM9.41%Amplitude2.005Historical Low3.512Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
CVAC, SBNY and CRMD Are Among After Hour Movers
Analysts Just Made A Massive Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Forecasts
Sutro Biopharma, Inc. (NASDAQ:STRO) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. The analysts greatly increased t
Sutro Biopharma Is Maintained at Outperform by Oppenheimer
Sutro Biopharma Is Maintained at Outperform by Oppenheimer
Express News | Truist Securities Maintains Buy on Sutro Biopharma, Lowers Price Target to $18
Sutro Biopharma Price Target Maintained With a $17.00/Share by JMP Securities
Sutro Biopharma Price Target Maintained With a $17.00/Share by JMP Securities
Express News | JMP Securities Reiterates Market Outperform on Sutro Biopharma, Maintains $17 Price Target
Comments
Gear up for AACR24!
See Biotech companies with cancer assets 👇
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US$ : FPI-2265 (Ph 2)
$GRCL: ...
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US$ : FPI-2265 (Ph 2)
$GRCL: ...
9
$Sutro Biopharma(STRO.US$ Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering
GlobeNewswire· 10 mins ago
GlobeNewswire· 10 mins ago
1
Update
$Sutro Biopharma(STRO.US$ Sutro Biopharma Inc (STRO) has provided an announcement.
Sutro Biopharma, Inc. has secured a lucrative Exclusive License Agreement with Ipsen Pharma SAS to grant exclusive rights for the research, development, manufacture, and commercialization of STRO-003, a promising biopharmaceutical product. Ipsen has committed to an initial payment of $50 million and an investment of $25 million in Sutro Biopharma’s shares at a premium. Additional financial milestones includ...
Sutro Biopharma, Inc. has secured a lucrative Exclusive License Agreement with Ipsen Pharma SAS to grant exclusive rights for the research, development, manufacture, and commercialization of STRO-003, a promising biopharmaceutical product. Ipsen has committed to an initial payment of $50 million and an investment of $25 million in Sutro Biopharma’s shares at a premium. Additional financial milestones includ...
1
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg